Achieve Life Sciences
ACHVAchieve Life Sciences is a late-stage clinical specialty pharmaceutical company focused on addressing the global nicotine dependence epidemic.
Earnings
Next report
Nov 5, 2026 (in 2 months)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
Profile
Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company focused on addressing the global nicotine dependence epidemic. The company's primary value proposition is the development and commercialization of cytisinicline, a naturally occurring alkaloid designed to treat both combustible cigarette smoking and e-cigarette nicotine addiction. By utilizing a dual-acting mechanism that reduces cravings and the reward associated with nicotine, the company aims to provide a safer and more effective alternative to existing cessation therapies.
Achieve is a late-stage developer of the first potential new prescription nicotine cessation medicine in two decades, holding Breakthrough Therapy and National Priority designations.
FAQ
- What is Achieve Life Sciences's market cap?
- Achieve Life Sciences (ACHV) has a market capitalization of $851.0M and trades on NASDAQ.
- Who are Achieve Life Sciences's competitors?
- Achieve Life Sciences's key competitors include Pfizer Inc., Sionna Therapeutics, Inc. Common Stock, Cyclerion Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Achieve Life Sciences partner with?
- Achieve Life Sciences's notable partners include Sopharma AD, Adare Pharma Solutions, University of Bristol, and others.
- What subsidiaries does Achieve Life Sciences have?
- Achieve Life Sciences's subsidiaries include Extab Corporation.
- Where is Achieve Life Sciences headquartered?
- Achieve Life Sciences is headquartered in Canada and employs approximately 22 people. It has been publicly traded since 1995.